Retrospective Study from a Single Center in Romania of 347 Renal Transplant Patients Treated with Tacrolimus, Mycophenolate, and Steroids to Evaluate the Association Between Anti-HLA Antibodies and 5-Year Graft Survival

12 August 2022 : Original article

Ion Mărunţelu^12ABCDEF, Claudiu Eduard Nistor

^2CEF*, Bogdan Mihai Cristea^2CE, Corina Andreea Rotarescu^12BCD, Andreea Mirela Caragea^2B, Maria Tizu^2B, Ileana Constantinescu^12AD

DOI: 10.12659/AOT.937267

Ann Transplant 2022; 27:e937267

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 6 Hazard ratios with 95% confidence interval in patients without preformed anti-HLA antibodies.

Factor	Negative HLA antibodies	Positive HLA antibodies
Negative HLA antibodies	–	4.0251
Negative HLA antibodies	–	1.5574 to 10.4032
Positive HLA antibodies	0.2484
Positive HLA antibodies	0.09612 to 0.6421
HLA – human leukocyte antigen. In the non-HLA previous sensitized group, the estimated relative risk of the event of kidney graft loss occurring in the subgroup with de novo anti-HLA antibodies is 4.0251 greater than in the subgroup with no HLA antibodies.

Back to the Article